FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug

Details werden geladen...

FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug | FDA

FDA is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib.

This Experimental Drug Could Be a Game Changer for Pancreatic Cancer

Pharmalittle: We're reading about a pancreatic cancer pill, FDA rejecting a Replimune drug again, and more

ImmunityBio (IBRX) Shares Plunge 21% Following FDA Warning Letter on Misleading Cancer Drug Marketing - Blockonomi

The race to catch KRAS, pancreatic cancer’s ‘greasy ball,’ and create the most promising drug in decades

‘A year is a long time to wait’: Ontario speeds up cancer drug access | Globalnews.ca

Pharming Group Receives FDA Complete Response Letter For Joenja Pediatric SNDA | 02.02.26 | finanzen.ch

FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug | FDA

This Experimental Drug Could Be a Game Changer for Pancreatic Cancer

Pharmalittle: We're reading about a pancreatic cancer pill, FDA rejecting a Replimune drug again, and more

ImmunityBio (IBRX) Shares Plunge 21% Following FDA Warning Letter on Misleading Cancer Drug Marketing - Blockonomi

The race to catch KRAS, pancreatic cancer’s ‘greasy ball,’ and create the most promising drug in decades

‘A year is a long time to wait’: Ontario speeds up cancer drug access | Globalnews.ca

Pharming Group Receives FDA Complete Response Letter For Joenja Pediatric SNDA | 02.02.26 | finanzen.ch